Changing Practice Patterns in CKD
Closing out the discussion, an expert in chronic kidney disease (CKD) highlights how care for patients with CKD may change in the future based on data presented at AMCP.
Clinical and Humanistic Burden of IgA Nephropathy
Robert Toto, MD, provides his expert opinion regarding recent data from Forsythe, et al about the clinical and humanistic burden of IgA nephropathy.
IgA Nephropathy Data: US Incident Population
An expert in chronic kidney disease (CKD) provides a recap of data, recently released at AMCP, around the estimate of the US incident population of IgA nephropathy.
Implications of Dapagliflozin Analysis in CKD
An overview of the implications of the recent dapagliflozin data in chronic kidney disease (CKD) treatment to US clinicians and payers.
Results from DAPA-CKD: Time-to-Event and Cost Consequence
An expert in chronic kidney disease (CKD) discusses the importance of showing data at the 3-year mark for the DAPA-CKD study, released at AMCP.
Analysis from DAPA-CKD: Time-to-Event and Cost Consequence
Robert Toto, MD, recaps another recent analysis of data from DAPA-CKD that looked at the time-to-event and cost consequence of delaying clinical events in chronic kidney disease (CKD).
Findings From the DAPA-CKD Study: Reductions in Healthcare Resource Utilization
A recap of the dapagliflozin data from the DAPA-CKD study and how it relates to reductions in healthcare resource utilization.
New Data From AMCP: DAPA-CKD Study
An expert in chronic kidney disease (CKD) provides an overview of healthcare resource utilization data from the DAPA-CKD study, which was recently released at AMCP.
CKD: Healthcare Resource Utilization
Robert Toto, MD, discusses key factors of healthcare resource utilization for patients with chronic kidney disease (CKD) and gives an overview of the link between CKD and cardiovascular disease.
